CA2985330A1 - Methods for the treatment of bladder cancer - Google Patents

Methods for the treatment of bladder cancer

Info

Publication number
CA2985330A1
CA2985330A1 CA2985330A CA2985330A CA2985330A1 CA 2985330 A1 CA2985330 A1 CA 2985330A1 CA 2985330 A CA2985330 A CA 2985330A CA 2985330 A CA2985330 A CA 2985330A CA 2985330 A1 CA2985330 A1 CA 2985330A1
Authority
CA
Canada
Prior art keywords
mitomycin
prodrug
liposomal
bladder cancer
folate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2985330A
Other languages
English (en)
French (fr)
Inventor
Alberto Gabizon
Patricia OHANA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipomedix Pharmaceuticals Ltd
Original Assignee
Lipomedix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipomedix Pharmaceuticals Ltd filed Critical Lipomedix Pharmaceuticals Ltd
Publication of CA2985330A1 publication Critical patent/CA2985330A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2985330A 2015-03-17 2016-03-17 Methods for the treatment of bladder cancer Pending CA2985330A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562134328P 2015-03-17 2015-03-17
US62/134,328 2015-03-17
PCT/US2016/022909 WO2016149516A1 (en) 2015-03-17 2016-03-17 Methods for the treatment of bladder cancer

Publications (1)

Publication Number Publication Date
CA2985330A1 true CA2985330A1 (en) 2016-09-22

Family

ID=56919480

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2985330A Pending CA2985330A1 (en) 2015-03-17 2016-03-17 Methods for the treatment of bladder cancer

Country Status (6)

Country Link
US (1) US20180071253A1 (enExample)
EP (1) EP3270898B1 (enExample)
JP (2) JP6859275B2 (enExample)
AU (1) AU2016233143B2 (enExample)
CA (1) CA2985330A1 (enExample)
WO (1) WO2016149516A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3126211A1 (en) * 2019-01-11 2020-07-16 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
WO1998007409A1 (en) 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
EP1880736A1 (en) 1999-04-23 2008-01-23 Alza Corporation Releasable linkage and composition containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
EP1504010B1 (en) * 2002-05-15 2009-03-25 Endocyte, Inc. Vitamin-mitomycin conjugates
WO2015191576A1 (en) * 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy

Also Published As

Publication number Publication date
AU2016233143A1 (en) 2017-10-19
EP3270898A4 (en) 2018-10-31
JP6859275B2 (ja) 2021-04-14
JP2021035973A (ja) 2021-03-04
AU2016233143B2 (en) 2021-03-25
WO2016149516A1 (en) 2016-09-22
US20180071253A1 (en) 2018-03-15
JP2018508589A (ja) 2018-03-29
EP3270898A1 (en) 2018-01-24
EP3270898B1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
US11173178B2 (en) Liposomes for drug delivery and methods for preparation thereof
Hossann et al. In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes
KR100889139B1 (ko) 이리노테칸 제제
KR101925507B1 (ko) 조절 약물 방출 리포솜 조성물
US20120100206A1 (en) Targeted liposomes comprising n-containing bisphosphonates and uses thereof
JP2018505224A (ja) ナノ粒子を含む組成物並びに腫瘍を治療する方法
US20080026049A1 (en) Liposomal compositions for parenteral delivery of agents
BRPI0009448B1 (pt) kit para uso no tratamento de uma neoplasia em um mamífero
US20030082228A1 (en) Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
US20240173257A1 (en) Liposome formulations
US20190216932A1 (en) Controlled drug release liposome compositions and methods thereof
JP2003522193A (ja) ホスホリパーゼａ２で分解可能な脂質誘導体を含有する脂質をベースとした薬物送達系、および治療におけるその使用
AU2016233143B2 (en) Methods for the treatment of bladder cancer
WO2022153211A1 (en) Liposomal composition of a camptothecin derivative
CA2570329C (en) Liposome preparation containing slightly water-soluble camptothecin
US20220378936A1 (en) Delivery system complexes comprising a precipitate of an active agent and methods of use
US20250268827A1 (en) Combined medicinal drug including liposome composition encompassing topotecan or salt thereof and dna damage repair inhibitor
Messerer Liposomal encapsulation of irinotecan and potential for the use of liposomal drug in the treatment of liver metastases associated with advanced colorectal cancer
JP2003221336A (ja) 抗悪性腫瘍剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210225

EEER Examination request

Effective date: 20210225

EEER Examination request

Effective date: 20210225

EEER Examination request

Effective date: 20210225

EEER Examination request

Effective date: 20210225

EEER Examination request

Effective date: 20210225

EEER Examination request

Effective date: 20210225